Will Glaxo recall a Blockbuster because it’s Harmful ?

07 Sep

MJ questions safety profile of Avandia.  Amplify’d from

GlaxoSmithKline responds to calls in BMJ to withdraw Avandia

Firstword - Plus Light Edition?pslrid=9CDC8DBF06754E0784D3DAAF65C49804 - Where people who know first, go first

The article questioned whether there was sufficient clinical data available in 2000 when the product was approved in Europe, and also raised concerns about the quality of data submitted by GlaxoSmithKline, the lack of publicly available trial results for independent scientific scrutiny, and failures to act swiftly on emerging safety fears.

Leave a comment

Posted by on September 7, 2010 in Uncategorized


Tags: , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: